Oncternal Therapeutics Hematological Malignancies and Prostate Cancer KOL Webinar
|DATE:||January 25, 2022|
|TIME:||12:00 AM EST|
About The Event
The webinar will feature a presentation by Key Opinion Leader (KOL) Michael Wang, M.D. (MD Anderson Cancer Center), who will discuss the current treatment landscape and unmet medical need in treating Mantle Cell Lymphoma.
Oncternal’s management team will also discuss details of its novel enrichment design for Zilovertamab’s Phase 3 registrational trial planned for 2022, after reaching consensus with the FDA.
A second KOL, Evan Ya-Wen Yu, M.D. (Fred Hutchinson Cancer Research Center) will provide perspectives on current standards of care and highlight the potential of next generation treatments for patients with advanced prostate cancer.
Oncternal’s management team will also discuss details of ONCT-534, a novel dual action androgen receptor inhibitor (DAARI), pre-clinical data and development plans.
A live question and answer session will follow the formal presentations.